DM CLL cells were more sensitive to this combination treatment than all the other 3 groups (P < 0.001, 2-way ANOVA) (Figure 5G), corroborating our observation in murine CLL cells, highlighting that RNA splicing and mTOR pathways are essential for DM CLL cells. The gene discussed is MTOR; the disease is B-cell chronic lymphocytic leukemia.